Don’t leave drug development to chance.

Your AI agent, in production.

Tempus One is an AI agent embedded directly in the Lens environment. It doesn’t just answer questions about your data—it does the work for you.

By typing in plain language, you can assemble a relevant cohort, generate an analysis for your research question, create a real-world comparator to contextualize your study, or generate clinical evidence – all in a matter of minutes.

Uncover critical signals from complex disease biology.

Tempus One reads multimodal databases in seconds, not weeks.

Pose a biomarker hypothesis, and Tempus One assembles relevant signals from multimodal data across DNA, RNA, digital pathology, radiology imaging, and longitudinal clinical outcomes to surface patient subpopulations and disease biology predictive of overall survival. Every result is auditable and traceable.

Stress test protocol concept with feasibility results instantly.

Real-world control arm. Real-world site list. Real-world enrollment projection.

Upload a study protocol or describe your analysis plan. Tempus One will leverage real-world multimodal data to build your cohort, validate it against eligibility criteria, generate a real-world comparator, project enrollment timelines by region, and flag the protocol amendments most likely to materially impact the trial.

Run end-to-end analyses

Produce interactive analysis reports, such as gene co-expression, biomarker prevalence, treatment landscape, and real-world survival analysis, without writing a line of code. Easily share results and code with technical colleagues for further analysis in a secure coding environment.

Train foundation models

Leverage compute infrastructure with scalable CPU/GPU configurations to train foundation models on HIPAA-compliant de-identified patient data, all within a secure, fully governed dedicated environment—no engineering tickets or data pipeline transfers required.

Customer success stories.

See why Tempus is a trusted partner for 95% of the top 20 pharma companies* and more than 250 biopharma companies.

*based on publicly available 2024 segment revenue